MM3122|CAS 2574390-27-3|DC Chemicals

Cas No.:	2574390-27-3
Chemical Name:	MM3122
Synonyms:	MM-3122; MM 3122
SMILES:	CC(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCNC(N)=N)C(C2=NC3=CC=CC=C3S2)=O)=O)=O)=O)=O
Formula:	C₃₁H₃₉N₉O₆S
M.Wt:	665.74
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Matthew Mahoney, et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc Natl Acad Sci U S A. 2021 Oct 26;118(43):e2108728118.

Description:	MM3122 is a selective inhibitor of host cell serine protease TMPRSS2 (transmembrane protease serine 2) with IC50 of 0.34 nM against recombinant full-length TMPRSS2 protein.
References:	[1]. Matthew Mahoney, et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc Natl Acad Sci U S A. 2021 Oct 26;118(43):e2108728118.

Cat. No.	Product name	Field of application
DC71900	MM3122	MM-3122 is a selective inhibitor of host cell serine protease TMPRSS2 (transmembrane protease serine 2) with IC50 of 0.34 nM against recombinant full-length TMPRSS2 protein.
DC42577	SSAA09E2	SSAA09E2 is a novel inhibitor of SARS-CoV replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2)
DC33651	ML188	ML188 is a Potent Noncovalent Small Molecule Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. The X-ray structure of SARS-CoV 3CLpro bound with ML188 was instrumental in guiding subsequent rounds of chemistry optimiz
DC10662	GC-376	GC376 is a novel, first-in-class, small molecule protease inhibitor with a favorable therapeutic index demonstrated in preclinical studies. A common feature of viruses in the picornavirus-like supercluster (including coronaviruses) is a 3C or 3C-like prot
DC20446	Mefuparib hydrochloride(CVL218)	Mefuparib(CVL218) hydrochloride is a potent, highly selective, competitive PARP1/2 inhibitor with IC50 of 3.2/1.9 nM, respectively.CVL218 was more potent than Remdesivir in blocking Coronavirus infection of cells and equally as potent as Remdesivir in blocking replication of virus once it has entered the cells.
DC11407	Asapiprant(BGE-175)	Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit
DC22771	Proxalutamide	Proxalutamide (GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) for the potential treatment of COVID-19, prostate cancer, and breast cancer.